Advertisement
UK markets open in 7 hours 54 minutes
  • NIKKEI 225

    39,154.85
    -439.54 (-1.11%)
     
  • HANG SENG

    17,311.05
    -158.31 (-0.91%)
     
  • CRUDE OIL

    77.54
    -0.05 (-0.06%)
     
  • GOLD FUTURES

    2,396.70
    -19.00 (-0.79%)
     
  • DOW

    39,853.87
    -504.22 (-1.25%)
     
  • Bitcoin GBP

    50,570.78
    -577.01 (-1.13%)
     
  • CMC Crypto 200

    1,342.08
    -23.82 (-1.74%)
     
  • NASDAQ Composite

    17,342.41
    -654.94 (-3.64%)
     
  • UK FTSE All Share

    4,468.59
    -10.90 (-0.24%)
     

Prothena to Report First Quarter 2024 Financial Results on May 8

DUBLIN, Ireland, May 01, 2024--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets.

Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on May 8.

About Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20240501774932/en/

Contacts

Investors
Mark Johnson, CFA, Vice President, Investor Relations
650-417-1974, mark.johnson@prothena.com

Media
Michael Bachner, Senior Director, Corporate Communications
609-664-7308, michael.bachner@prothena.com